ProfileGDS5678 / 1455761_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 52% 51% 51% 51% 51% 52% 52% 50% 50% 50% 51% 51% 51% 51% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3019952
GSM967853U87-EV human glioblastoma xenograft - Control 23.2154251
GSM967854U87-EV human glioblastoma xenograft - Control 33.2237851
GSM967855U87-EV human glioblastoma xenograft - Control 43.1668651
GSM967856U87-EV human glioblastoma xenograft - Control 53.1662551
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3775852
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3348352
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1967750
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.186750
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1737950
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2102251
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1916351
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2238551
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2167251